Circulating vaccine-derived polioviruses: current state of knowledge
about
Poliomyelitis and the postpolio syndromeCirculation of type 1 vaccine-derived poliovirus in the Philippines in 2001Antiviral activity of 3(2H)- and 6-chloro-3(2H)-isoflavenes against highly diverged, neurovirulent vaccine-derived, type2 poliovirus sewage isolatesNeurovirulent vaccine-derived polioviruses in sewage from highly immune populations.Co-circulation and evolution of polioviruses and species C enteroviruses in a district of Madagascar.Impact of exogenous sequences on the characteristics of an epidemic type 2 recombinant vaccine-derived poliovirus.Limited duration of vaccine poliovirus and other enterovirus excretion among human immunodeficiency virus infected children in KenyaNatural type 3/type 2 intertypic vaccine-related poliovirus recombinants with the first crossover sites within the VP1 capsid coding region.Chimpanzee-human monoclonal antibodies for treatment of chronic poliovirus excretors and emergency postexposure prophylaxis.Limited and localized outbreak of newly emergent type 2 vaccine-derived poliovirus in Sichuan, China.Listening to the rumours: what the northern Nigeria polio vaccine boycott can tell us ten years on.Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient.From emergence to eradication: the epidemiology of poliomyelitis deconstructedDeterminants of routine immunization coverage in Bungudu, Zamfara State, Northern Nigeria, May 2010Antigenic evolution of vaccine-derived polioviruses: changes in individual epitopes and relative stability of the overall immunological propertiesAn outbreak of type π vaccine-derived poliovirus in Sichuan province, China: emergence and circulation in an under-immunized population.Sequential asymptomatic enterovirus infections in a patient with major histocompatibility complex class II primary immunodeficiencyEvolution and circulation of type-2 vaccine-derived polioviruses in Nad Ali district of Southern Afghanistan during June 2009-February 2011.So close: remaining challenges to eradicating polioSailing in Uncharted Waters: Carefully Navigating the Polio Endgame.An Insight into Recombination with Enterovirus Species C and Nucleotide G-480 Reversion from the Viewpoint of Neurovirulence of Vaccine-Derived Polioviruses.High susceptibility for enterovirus infection and virus excretion features in Tunisian patients with primary immunodeficiencies.Detection of non-polio enteroviruses from 17 years of virological surveillance of acute flaccid paralysis in the Philippines.Sabin Vaccine Reversion in the Field: a Comprehensive Analysis of Sabin-Like Poliovirus Isolates in Nigeria.Sabin and wild type polioviruses from children who presented with acute flaccid paralysis in Nigeria.Changes in population dynamics during long-term evolution of sabin type 1 poliovirus in an immunodeficient patientEnvironmental poliovirus surveillance during oral poliovirus vaccine and inactivated poliovirus vaccine use in Córdoba Province, ArgentinaEmergence of vaccine-derived polioviruses, Democratic Republic of Congo, 2004-2011.Long-term excretion of vaccine-derived poliovirus by a healthy child.Spread of vaccine-derived poliovirus from a paralytic case in an immunodeficient child: an insight into the natural evolution of oral polio vaccine.Addressing the Challenges and Opportunities of the Polio Endgame: Lessons for the Future.Unique safety issues associated with virus-vectored vaccines: Potential for and theoretical consequences of recombination with wild type virus strains.Introduction of Inactivated Polio Vaccine, Withdrawal of Type 2 Oral Polio Vaccine, and Routine Immunization Strengthening in the Eastern Mediterranean Region.Rational design of genetically stable, live-attenuated poliovirus vaccines of all three serotypes: relevance to poliomyelitis eradication.Development of enhanced antibody response toward dual delivery of nano-adjuvant adsorbed human Enterovirus-71 vaccine encapsulated carrier.Prolonged Excretion of Poliovirus among Individuals with Primary Immunodeficiency Disorder: An Analysis of the World Health Organization Registry.The risk of type 2 oral polio vaccine use in post-cessation outbreak response.Shedding and reversion of oral polio vaccine type 3 in Mexican vaccinees: comparison of mutant analysis by PCR and enzyme cleavage to a real-time PCR assay.Vaccine-derived poliovirus surveillance in China during 2001-2013: the potential challenge for maintaining polio free status.Evolution of echovirus 11 in a chronically infected immunodeficient patient.
P2860
Q24555519-1F8D8AB9-EEB6-4F14-96C8-C796BDD036CCQ24559785-AE140F5B-349B-4025-B615-AA6EFCAE9B2EQ28478276-5542CAF4-286B-4267-9F34-E10E21168DBAQ33267329-DC0C089B-0BAF-408E-B807-3B1C922E7494Q33310740-72839CD2-DA6D-4EF7-A9D2-63A365A2D2BEQ33346729-7A320124-63E6-475B-B157-5E1D295F726EQ33495786-37F9D41B-557E-4781-9B8D-CB68F04AF847Q33784842-AC1B4A34-FF18-4D40-B497-CBB6B4B4FC24Q33827773-FD43BD0D-EB73-4ADA-BBF2-70758C47DD8CQ33899399-D59A6283-9F67-4587-92CB-ED9F6BED42D4Q33901420-EDFE1C81-DBC1-4F39-B886-743CA892E929Q34045658-3431C2B5-BDD9-4187-B620-A5725EE1861CQ34349482-75A2C51C-6D74-40E5-B250-C86E6570B468Q34349877-5705521A-CCC9-4029-A4DE-39ED6FF74B0AQ34435032-8FF65131-C7D3-46ED-B512-6AF0B73BE1D3Q34680514-A3D9E984-03D0-461C-BE61-6304D897E00AQ35035879-87C3E1F5-99BB-40CA-B661-47401ABF7AE5Q35099564-60BA4ED1-AC46-4D51-AD5B-C45BF9D7444AQ35955372-85A63BFB-C67C-46C1-8C5F-60D84A29DF35Q36152634-3F61B619-882C-41A4-A347-F54C761B817EQ36316673-5A130C2C-22C4-4240-93D4-59DA7EC26450Q36362236-B707EDFB-0406-46F2-AB2E-1620E8FF0703Q36406152-4A0EDD1E-322D-496D-AD0F-61F6600EB5A2Q36433974-13C24949-C5F7-40C9-BE03-6AA7035B988FQ36569781-19A32750-2865-4616-BFCF-0AA28A56B57FQ36898727-10AF1079-A637-42F4-A755-8630BD84F829Q37110431-3F88696D-7590-4813-AC4B-257362A1A465Q37261927-48916585-AB18-4A2F-9681-461D093CB701Q37683100-9B8AA0F5-A8B3-499E-8C4B-3FF1B1AAA411Q37743865-643728BC-AAB2-404C-A5A2-FEA993241035Q38637663-0CDFE186-B99D-4DFA-883F-A5ADD46407FFQ38848322-FC406D16-23B8-493D-9977-997A9243E289Q39201541-1698049B-0858-4DE5-884D-FD0B34359235Q40243124-9AA2E9A6-4226-46C8-8E28-99655469ADEDQ41575418-50356B15-A1D1-4586-BA51-B1BCCBCE0A3DQ41921219-336F2ADA-D5B6-4B2F-B808-BAF92E6B1338Q41925239-576B5FAF-E086-43D0-B757-41F45422DECAQ42413057-CE25D070-87EA-49A7-8B66-965E517EAEB4Q47110369-0F9C144F-36D7-4681-AABF-494AC485949CQ52648772-ADC16314-4FEB-4584-A5BA-9C35CF357C17
P2860
Circulating vaccine-derived polioviruses: current state of knowledge
description
2004 nî lūn-bûn
@nan
2004 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Circulating vaccine-derived polioviruses: current state of knowledge
@ast
Circulating vaccine-derived polioviruses: current state of knowledge
@en
Circulating vaccine-derived polioviruses: current state of knowledge
@nl
type
label
Circulating vaccine-derived polioviruses: current state of knowledge
@ast
Circulating vaccine-derived polioviruses: current state of knowledge
@en
Circulating vaccine-derived polioviruses: current state of knowledge
@nl
prefLabel
Circulating vaccine-derived polioviruses: current state of knowledge
@ast
Circulating vaccine-derived polioviruses: current state of knowledge
@en
Circulating vaccine-derived polioviruses: current state of knowledge
@nl
P2093
P3181
P1476
Circulating vaccine-derived polioviruses: current state of knowledge
@en
P2093
Francis Delpeyroux
Hiroyuki Shimizu
Neal Nathanson
Olen M Kew
Peter F Wright
Vadim I Agol
P3181
P407
P577
2004-01-01T00:00:00Z